Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390208 · ClinicalTrials.gov registry record · Phase 2
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
A Phase 2 study of Age-related Macular Degeneration, sponsored by Bay Area Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT00390208 is a Phase 2 study of Age-related Macular Degeneration that has completed, run by Bay Area Retina Associates. The registered enrollment target is 60 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00390208, a Phase 2 study of Age-related Macular Degeneration, has completed, sponsored by Bay Area Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG ranibizumab, dexamethasone and verteporfin
Study Locations (4)
California
- Bay Area Retina Associates - Castro Valley
- Bay Area Retina Associates - Walnut Creek
Georgia
- Georgia Retina - Riverdale
Ohio
- Retina Vitreous Associates - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390208
The ClinicalTrials.gov registry entry for NCT00390208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Bay Area Retina Associates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00390208 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT00390208 about?
NCT00390208 is a clinical study titled "Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration". The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of Age-Related Macular Degeneration.
What is the current status of trial NCT00390208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-08. Estimated completion is 2009-12.
What conditions does trial NCT00390208 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT00390208?
The interventions under investigation include: Ranibizumab (DRUG), ranibizumab, dexamethasone and verteporfin (DRUG).
Who is sponsoring clinical trial NCT00390208?
This trial is sponsored by Bay Area Retina Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390208 being conducted?
This trial has 4 study locations across California, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.